Efficacy and safety of TQ-B3101 as postoperative adjuvant therapy for completely resected stage IB-IIIA non-small cell lung cancer with uncommon ROS1 mutations

开始日期2025-05-01

申办/合作机构

上海市肺科医院

NCT06925048

/ Not yet recruiting临床2期IIT

A Multi-cohort, Phase II Study of SHR0302 Combined With PD-1/PD-L1 Inhibition for Treatment naïve or Acquired Resistant to Immunology NSCLC

Recent studies showed that the dysregulated activation of the JAK/STAT pathway, which leads to the prolonged release of IFN-γ, is a significant contributor to the resistance to immune checkpoint inhibitors in cancer immunotherapy. Preclinical and clinical studies have demonstrated that the combination of JAK inhibitors with PD-1 immunotherapy can reverse or delay onset of immunotherapy resistance by modulating the JAK/STAT pathway in Hodgkin's lymphoma and non - small cell lung cancer (NSCLC). SHR0302, being a highly selective JAK1 inhibitor, has shown excellent clinical benefits by effectively inhibiting the JAK/STAT pathway, leading to its approval for the treatment of Ankylosing Spondylitis in China. Preclinical studies also show that the combination of SHR0302 and PD-L1 inhibitor has synergistic potentials for anti-tumor effect in resistant to-immune checkpoint blockade patients. Thus, we conducted a phase 2 clinical trial evaluating SHR0302 combined with PD1/PD-L1 inhibitors as treatment-naïve or acquired resistant to first-line checkpoint inhibitor resistant NSCLC patients.

开始日期2025-04-30

申办/合作机构

上海市肺科医院

NCT06895941

/ WithdrawnN/AIIT

Predictive Value of PET/CT for Efficacy of Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer

The aim of this study was to investigate the enhancement of FAPI PET/CT metabolic parameters in predicting the efficacy performance of neoadjuvant immunotherapy using the pCR status of surgically resected specimens of lung cancer as the gold standard.

开始日期2025-04-30

申办/合作机构

上海市肺科医院

100 项与上海市肺科医院相关的临床结果

登录后查看更多信息

0 项与上海市肺科医院相关的专利（医药）

登录后查看更多信息

699

项与上海市肺科医院相关的文献（医药）

2025-08-01·Neuropharmacology

Kinsenoside attenuates ER stress and inhibits inflammatory responses through IL-10/STAT/SOCS3 pathway in chronic pain relief

Article

作者: Ma, Le ; Deng, Mengjiao ; Wei, Jinbao ; Chi, Qingqing ; Duan, Dongxia ; Ding, Ronghua ; Xi, Yufei ; Ding, Yingzhuo ; Fu, Xia ; Wang, Wei ; Yu, Chunxia ; Li, Qin

Neuro-inflammation contributes to neuropathic pain by sensitizing ionic channels. Kinsenoside, a traditional Chinese medicine, has recognized anti-inflammatory properties. However, it remains unclear whether kinsenoside can be used for pain therapy. Network pharmacology analysis revealed that 57 % of its targets are associated with pain, including inflammation and synaptic transmission. The analgesic effects of kinsenoside were confirmed in SNL and formalin rat models, with ED50 values of 47.99 μg and 36.80 μg, respectively. Transcriptome and WGCNA analyses indicated the involvement of cytokine release, anti-inflammatory activity, and synapse enrichment in the blue module. Furthermore, we confirmed that kinsenoside's efficacy was mainly mediated by IL-10 induction, phosphorylation of STAT3, and SOCS3 expression. Pretreatment with kinsenoside significantly inhibited the release of TNF-α, IL-1β, and IL-6. Kinsenoside also attenuated ER stress in both microglia and neural cells. Molecular docking analysis demonstrated significantly high binding energies of IL-10, STAT3, and SOCS3 with MHC. Additionally, whole-cell recordings revealed that bath application of kinsenoside reduced the frequency and amplitude of spinal glutamatergic transmission in a dose-dependent manner. In summary, pharmacological prediction and biological validation collectively indicate that kinsenoside significantly exerts significant analgesic effects by attenuating ER stress and inhibiting inflammatory responses via the IL-10/p-STAT3/SOCS3 axis, precisely regulating spinal glutamatergic transmission for pain relief.

2025-06-01·MethodsX

Spinal ultrasound imaging implied the vascular dynamics in chronic and acute pain

Article

作者: Xi, Yufei ; Duan, Dongxia ; Wei, Jinbao ; Chi, Qingqing ; Deng, Mengjiao ; Li, Qin ; Yu, Chunxia ; Ma, Le ; Ding, Yingzhuo

Neurovascular coupling links local neural activity to cerebral blood flow changes, crucial for pain transduction. In this undertaking, we present an advanced spinal functional ultrasound imaging that exhibits precise observation capabilities of the influence of analgesic medications on spinal cord blood flow, encompassing both acute and chronic pain scenarios. Utilizing gabapentin as the primary analgesic agent, we have observed that intrathecal administration of gabapentin notably augments the blood flow intensity in neuropathic rats while exerting minimal influence on the blood flow of the sham rats. Furthermore, subcutaneous formalin injection increases spinal cord blood flow, but gabapentin pretreatment prevents those effects. These findings demonstrated the analgesic effect of gabapentin exhibits a synergistic interaction with the intensity of blood flow around neurons, which is crucial for understanding the mechanisms underlying the occurrence of pain. In this article, we show: • A simple method to build the spinal cord ligation-induced chronic pain model. • A generic way to build the formalin-induced acute pain model. • An optimized functional ultrasound imaging technique in chronic and acute pain.

2025-04-25·Cancer Research

Abstract CT126: Aumolertinib as adjuvant therapy in patients with stage II-IIIB EGFR-mutated NSCLC after complete tumor resection: A randomized, double-blind, placebo-controlled, phase 3 trial (ARTS)

作者: Gao, Zhenyuan ; Liu, Jixian ; Zhang, Zhenfa ; Chen, Kai ; Yang, Li ; Xu, Zhi ; Ji, Yinghua ; Fan, Shaonan ; Wang, Minghui ; Tian, Hui ; Xie, Chanjuan ; Gong, Huiyuan ; Xing, Wenqun ; Ge, Di ; Wang, Wenxiang ; Li, Shujun ; Liu, Xianling ; Zhao, Xin ; Fang, Haohui ; Liu, Caigang ; Zang, Aimin ; Liu, Hongxu ; Xu, Shidong ; Liu, Lunxu ; Gao, Yang ; Li, Xingya ; Shi, Jianhua ; Chen, Zhenmin ; Guo, Renhua ; Zhang, Xiqin ; Liu, Chunling ; Dong, Xiaorong ; Chen, Liang ; Xu, Yan ; Geng, Qing ; Cheng, Ying ; Zhang, Peng ; Xiong, Fei ; Li, Juan ; Su, Zhenzhong ; Ye, Min ; Cao, Lejie ; Zhang, Xiaodong ; Wu, Lin ; Li, Gaofeng ; Yu, Xinmin ; Hu, Jian ; Chen, Jun ; Dai, Zhaoxia

AbstractBackground:Lung cancer is the primary cause of cancer-related morbidity and mortality globally. Approximately 30% of patients with EGFR mutation (EGFRm) in NSCLC are diagnosed at an early stage and are candidates for curative-intent surgical resection; however, disease recurrence remains a substantial clinical challenge. Aumolertinib is a third-generation EGFR TKI that potently inhibits both sensitizing EGFR mutations (ex19del/L858R) and the resistance mutation T790M. ARTS (NCT04687241) is a randomized, double-blind, placebo-controlled, multicenter, phase 3 trial designed to evaluate the efficacy and safety of adjuvant aumolertinib versus placebo in patients with stage II-IIIB EGFRm NSCLC after complete resection, with or without adjuvant chemotherapy.Methods:Inclusion criteria included patients aged ≥18 years, ECOG PS 0-1, primary non-squamous stage II/IIIA/IIIB (T3N2M0) NSCLC, confirmed EGFRm (ex19del or L858R), complete resection with full postsurgical recovery, with or without postoperative adjuvant chemotherapy. Patients were randomized in a 1:1 ratio to receive aumolertinib (110 mg orally, once daily) or matched placebo for a planned treatment duration of 3 years. Stratification was based on stage (II, IIIA N2-, IIIA/B N2+) and mutation type (ex19del, L858R). The primary endpoint was disease-free survival (DFS), assessed by blinded independent central review (BICR). Secondary endpoints included investigator-assessed DFS, overall survival (OS), and safety profile. Data cutoff (DCO): April 15, 2024.Results:A total of 214 patients from China were randomized to treatment (Aumolertinib n=107, Placebo n=107). Baseline characteristics were balanced across treatment arms (aumolertinib/placebo): female 55.1%/57.0%, ever-smokers 28.0%/29.9%, stage II 44.9%/44.9%, stage III 54.2%/52.3%, ex19del 47.7%/50.5%, L858R 52.3%/49.5%, ECOG PS 0 36.4%/41.1%, ECOG PS 1 63.6%/58.9%. Median follow-up for DFS was 27.6 months. The mDFS assessed by BICR was not reached (95% CI, 29.1 to NA) in the aumolertinib arm versus 19.4 months (95% CI, 11.2 to 26.2) in the placebo arm; hazard ratio (HR) 0.166 (95% CI, 0.094 to 0.294); p<0.0001. The 2-year DFS rate was 88.2% in the aumolertinib arm versus 40.6% in the placebo arm. Investigator-assessed DFS was concordant with BICR assessment. OS data were immature at DCO (aumolertinib/placebo OS maturity: 2.8%/3.8%). The incidence of AEs leading to dose interruptions, dose reductions, and discontinuation in the aumolertinib/ placebo arm was 12.3%/ 17.8%, 9.4%/ 1.9%, and 0.9%/ 0, respectively. No new safety risks were observed.Conclusions:Adjuvant aumolertinib demonstrates a statistically significant and clinically meaningful improvement in DFS in patients with stage II-IIIB EGFRm NSCLC following complete tumor resection and adjuvant chemotherapy, when indicated. This DFS benefit underscores the promise of aumolertinib in fulfilling an unmet need for effective adjuvant EGFR-targeted therapy in early-stage NSCLC.Citation Format:Ying Cheng, Xiqin Zhang, Lin Wu, Wenxiang Wang, Wenqun Xing, Chunling Liu, Caigang Liu, Kai Chen, Jianhua Shi, Peng Zhang, Shidong Xu, Xiaodong Zhang, Xiaorong Dong, Haohui Fang, Xinmin Yu, Yang Gao, Gaofeng Li, Liang Chen, Huiyuan Gong, Renhua Guo, Zhenyuan Gao, Yinghua Ji, Lunxu Liu, Xianling Liu, Hui Tian, Fei Xiong, Xin Zhao, Lejie Cao, Qing Geng, Hongxu Liu, Jixian Liu, Li Yang, Zhenfa Zhang, Di Ge, Xingya Li, Minghui Wang, Yan Xu, Zhi Xu, Jun Chen, Zhaoxia Dai, Jian Hu, Juan Li, Shujun Li, Min Ye, Aimin Zang, Chanjuan Xie, Zhenzhong Su, Zhenmin Chen, Shaonan Fan. Aumolertinib as adjuvant therapy in patients with stage II-IIIB EGFR-mutated NSCLC after complete tumor resection: A randomized, double-blind, placebo-controlled, phase 3 trial (ARTS) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT126.

139

项与上海市肺科医院相关的新闻（医药）

2025-04-24

·ioncology

71个Oral，11个LBA！中国专家ASCO大会发言再创新高

点击上方蓝字关注我们编者按：一年一度的美国临床肿瘤学会（ASCO）年会即将来临。日前，ASCO公布了本次大会的摘要题目和大会日程。根据小编的手眼统计（如有纰漏请留言更正或增补），2025年ASCO大会上，中国专家的发言数量再创新高，共有71项原创性研究成果入选口头发言环节（Oral Abstract Session/Rapid Oral Abstract Session/Clinical Science Symposium），其中有11项研究将以重磅研究（Late Breaking Abstract，LBA）形式公布；此外，还有1项由北京大学肿瘤医院郭军教授的主旨演讲入选继续教育专场（Education Session）。01肺癌CAMPASS: Benmelstobart in combination with anlotinib vs pembrolizumab in the first-line treatment of advanced non-small cell lung cancer (aNSCLC): A randomized, single-blind, multicenter phase 3 study.CAMPASS：贝莫苏拜单抗联合安罗替尼对比帕博利珠单抗一线治疗晚期非小细胞肺癌：一项随机、单盲、多中心3期研究会议类型：Oral Abstract Session摘要号：LBA8502汇报者：韩宝惠（上海市胸科医院）Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET-amplification (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study.赛沃替尼联合奥希替尼对比化疗用于EGFR-TKI治疗进展后EGFR突变伴MET扩增的晚期非小细胞肺癌患者：来自3期随机SACHI研究结果会议类型：Oral Abstract Session摘要号：LBA8502汇报者：陆舜（上海市胸科医院）R-ALPS: A randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of TQB2450 with or without anlotinib as maintenance treatment in patients with locally advanced and unresectable (stage III) NSCLC without progression following concurrent or sequential chemoradiotherapy.R-ALPS：TQB2450 联合或不联合安罗替尼作为维持治疗在经同步或序贯放化疗后无进展的局部晚期不可切除（Ⅲ期）非小细胞肺癌患者中的随机、双盲、安慰剂对照、多中心Ⅲ期临床试验英文标题会议类型：Oral Abstract Session摘要号：LBA8004汇报者：陈明（中山大学肿瘤防治中心）phase 2 dose expansion study of ZG006, a trispecific T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with advanced small cell lung cancer一种靶向CD3/DLL3/DLL3的三特异性T细胞接合器ZG006单药治疗晚期小细胞肺癌患者的2期剂量扩展研究会议类型：Oral Abstract Session摘要号：8007汇报者：艾星浩（上海市肺科医院）SOHO-01: Safety and efficacy of BAY 2927088 in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC) who were pretreated but naïve to HER2-targeted therapy or had not received any treatment for advanced diseaseSOHO-01：BAY 2927088 用于既往接受过治疗但未接受 HER2 靶向治疗或未接受过任何治疗的晚期 HER2 突变非小细胞肺癌患者的安全性和有效性研究会议类型：Oral Abstract Session摘要号：8504汇报者：Herbert H. Loong（香港中文大学）Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study.Patritumab deruxtecan（HER3-DXd）用于经过第三代EGFR-TKI治疗后耐药的EGFR突变晚期非小细胞肺癌患者：3期HERTHENA-Lung 02研究会议类型：Oral Abstract Session摘要号：8506汇报者：莫树锦（香港中文大学）Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study.芦康沙妥珠单抗（sac-TMT）用于经治晚期EGFR突变非小细胞肺癌患者：来自OptiTROP-Lung03随机研究的结果会议类型：Oral Abstract Session摘要号：8507汇报者：张力（中山大学肿瘤防治中心）A phase II study of asandeutertinib (TY-9591) in advanced NSCLC patients with EGFR-positive mutations and brain metastases一项asandeutinib（TY-9591）治疗EGFR阳性突变伴脑转移的晚期NSCLC患者的II期研究会议类型：Oral Abstract Session摘要号：2004汇报者：石远凯（中国医学科学院肿瘤医院）Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with driver genomic alterations (GA) outside of classic EGFR mutations.EGFRxHER3 双特异性抗体药物偶联物iza-bren（BL-B01D1）治疗具有经典 EGFR 突变外的驱动基因改变（GA）的局部晚期或转移性非小细胞肺癌患者的I期研究会议类型：Oral Abstract Session摘要号：3001汇报者：杨云鹏（中山大学肿瘤防治中心）Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic small cell lung cancer (SCLC)EGFRxHER3 双特异性抗体药物偶联物iza-bren（BL-B01D1）在局部晚期或转移性小细胞肺癌患者中的Ⅰ期研究会议类型：Oral Abstract Session摘要号：3002汇报者：黄岩（中山大学肿瘤防治中心）First-in-class PD-1/IL-2 bispecific antibody IBI363 in patients (Pts) with advanced immunotherapy-treated non-small cell lung cancer (NSCLC)首创新药PD-1/IL-2双特异性抗体IBI363用于治疗经免疫治疗的晚期非小细胞肺癌（NSCLC）患者会议类型：Clinical Science Symposium摘要号：8509汇报者：周建娅（浙江大学医学院附属第一院）First report of efficacy and safety results from a phase 2 trial evaluating BNT327/PM8002 plus chemotherapy (chemo) as first-line treatment (1L) in unresectable malignant mesothelioma首个评估 BNT327/PM8002 联合化疗作为不可切除恶性胸膜间皮瘤一线治疗的 2 期试验的疗效及安全性结果报告会议类型：Clinical Science Symposium摘要号：8511汇报者：程颖（吉林省肿瘤医院）The preliminary results of a randomized phase II trial evaluating induction toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab in bulky unresectable stage III non-small-cell lung cancer (InTRist)一项评估特瑞普利单抗联合诱导化疗序贯同步放化疗及特瑞普利单抗巩固治疗用于巨大不可切除的III期非小细胞肺癌的随机II期试验（InTRist）的初步结果会议类型：Rapid Oral Abstract Session摘要号：8012汇报者：Yu Wang（中国医学科学院肿瘤医院）Phase 3 study of benmelstobart in combination with chemotherapy followed by sequential combination with anlotinib for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer (sq-NSCLC)benmelstobart单抗联合化疗序贯联合安罗替尼一线治疗局部晚期或转移性鳞状非小细胞肺癌（sq-NSCLC）的3期研究会议类型：Rapid Oral Abstract Session摘要号：8514汇报者：石远凯（中国医学科学院肿瘤医院）Randomized trial of relevance of time-of-day of immunochemotherapy for progression-free and overall survival in patients with non-small cell lung cancer非小细胞肺癌患者免疫化疗时间与无进展生存期及总生存期相关性的随机试验会议类型：Rapid Oral Abstract Session摘要号：8516汇报者：张永昌（湖南省肿瘤医院）Hypoxia-responsive CEA CAR-T cells therapy for relapsed or refractory non-small cell lung cancer: A single-arm, open-label, phase I trial缺氧反应型CEA CAR-T 细胞疗法治疗复发或难治性非小细胞肺癌：一项单臂、开放标签、I期试验会议类型：Rapid Oral Abstract Session摘要号：8517汇报者：魏双（华中科技大学同济医学院附属同济医院）Sosimerasib monotherapy in patients with previously treated KRAS G12C–mutated non-small cell lung cancer: Primary results of a phase 2 studySosimerasib单药治疗KRAS G12C突变非小细胞肺癌经治患者：2期研究的主要结果会议类型：Rapid Oral Abstract Session摘要号：8520汇报者：王洁（中国医学科学院肿瘤医院）02乳腺癌De-escalated neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2-positive early breast cancer (neoCARHP): A multicentre, open-label, randomised, phase 3 trial降阶紫杉类药物联合曲妥珠单抗和帕妥珠单抗±卡铂新辅助治疗HER2阳性早期乳腺癌（neoCARHP）：一项多中心、开放标签、随机、III期试验会议类型：Oral Abstract Session摘要号：LBA500汇报者：王坤（广东省人民医院）Dalpiciclib (Dalp) plus endocrine therapy (ET) as adjuvant treatment for HR+/HER2– early breast cancer (BC): The randomized, phase 3, DAWNA-A trial达尔西利联合内分泌治疗（ET）用于HR+/HER2–早期乳腺癌辅助治疗：随机、III期DAWNA-A试验会议类型：Rapid Oral Abstract Session摘要号：515汇报者：邵志敏（复旦大学附属肿瘤医院）HER2-ADC trastuzumab rezetecan (SHR-A1811) in HER2-positive breast cancer with brain metastases: Update results from REIN trialHER2-ADC trastuzumab rezetecan（SHR-A1811）用于HER2阳性乳腺癌脑转移患者：REIN试验最新结果会议类型：Rapid Oral Abstract Session摘要号：1017汇报者：闫敏（河南省肿瘤医院）A phase II clinical study of adebrelimab and bevacizumab combined with cisplatin/carboplatin in triple-negative breast cancer patients with brain metastases一项阿得贝利单抗联合贝伐珠单抗以及顺铂/卡铂用于脑转移三阴性乳腺癌患者的II期临床研究会议类型：Rapid Oral Abstract Session摘要号：1018汇报者：李婷（复旦大学附属肿瘤医院）Sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from the phase II OptiTROP-Breast05 study芦康沙妥珠单抗（Sac-TMT）用于不可切除局部晚期/转移性三阴性乳腺癌一线治疗：II期OptiTROP-Breast05研究初步结果会议类型：Rapid Oral Abstract Session摘要号：1019汇报者：殷咏梅（江苏省人民医院）Utidelone in combination with etoposide and bevacizumab in HER2-negative breast cancer patients with brain metastasis: A prospective, single-arm, phase II trial优替德隆联合依托泊苷和贝伐珠单抗治疗脑转移的HER2阴性乳腺癌症患者：一项前瞻性、单臂、II期试验会议类型：Rapid Oral Abstract Session摘要号：2012汇报者：史业辉（天津医科大学肿瘤医院）03结直肠癌Anlotinib versus bevacizumab added to standard first-line chemotherapy among patients with RAS/BRAF wild-type, unresectable metastatic colorectal cancer: A multicenter, prospective, randomised, phase 3 clinical trial (ANCHOR trial)安罗替尼对比贝伐珠单抗联合标准一线化疗用于RAS/BRAF 野生型、不可切除的转移性结直肠癌患者：一项多中心、前瞻性、随机、 3 期临床试验（ANCHOR试验）会议类型：Oral Abstract Session摘要号：LBA3502汇报者：丁克峰（浙江大学医学院附属第二医院）Efficacy and safety of IBI363 monotherapy or in combination with bevacizumab in patients with advanced colorectal cancerIBI363单药或联合贝伐珠单抗治疗晚期结直肠癌患者的疗效及安全性会议类型：Clinical Science Symposium摘要号：104汇报者：林振宇（华中科技大学同济医学院附属协和医院）JMT101 in combination with irinotecan and SG001 versus regorafenib in patients with metastatic colorectal adenocarcinoma (mCRC): Results of a randomized, controlled, open-label, phase II studyJMT101联合伊立替康和SG001对比瑞戈非尼治疗转移性结直肠腺癌（mCRC）患者：一项随机、对照、开放标签II期研究的结果会议类型：Rapid Oral Abstract Session摘要号：LBA3516汇报者：许剑民（复旦大学附属中山医院）Short-course radiotherapy followed by sintilimab and CAPOX as total neoadjuvant treatment in locally advanced rectal cancer: A prospective, randomized controlled trial (SPRING-01).短程放疗后序贯信迪利单抗和 CAPOX 作为局部晚期直肠癌的全程新辅助治疗：一项前瞻性、随机对照试验 (SPRING-01)会议类型：Rapid Oral Abstract Session摘要号：3519汇报者：靖昌庆（山东省立医院）04胃食管癌Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician's choice (TPC) for previously treated advanced gastric or gastroesophageal junction cancer (G/GEJC): Primary results from a randomized, open-label, phase II trial (CT041-ST-01)Claudin18.2-CAR T 细胞（Satri-cel）对比医生选择的治疗（TPC）用于经治的晚期胃或胃食管连接部癌（G/GEJC）：一项随机、开放标签、II 期试验（CT041-ST-01）的主要结果会议类型：Oral Abstract Session摘要号：4003汇报者：齐长松（北京大学肿瘤医院）Disitamab vedotin (DV) plus toripalimab (Tor) and chemotherapy (C)/trastuzumab (Tra) as first-line (1L) treatment of patients (pts) with HER2-expressing locally advanced or metastatic (la/m) gastric cancer维迪西妥单抗（DB）联合特瑞普利单抗（Tor）和化疗（C）/曲妥珠单抗（Tra）作为 HER2 表达局部晚期或转移性（la/m）胃癌患者的一线治疗会议类型：Rapid Oral Abstract Session摘要号：LBA4012汇报者：沈琳（北京大学肿瘤医院）Decoding the response and resistant features to the Claudin18.2-specific CAR-T cell CT041 in gastric cancer: A multi-omics exploratory biomarker analysis of the phase 1 clinical trial解析胃癌对 Claudin18.2- CAR-T 细胞 CT041 的反应和耐药特征：1期临床试验的多组学探索性生物标志物分析会议类型：Oral Abstract Session摘要号：4015汇报者：彭昊昕（北京大学肿瘤医院）Cosiporfin sodium (DVDMS)-mediated photodynamic therapy (PDT) versus treatment of physician’s choice (TPC) in patients (pts) with advanced esophageal cancer (aEC): A phase III, randomized, open-label, multicenter trialCosiporfin sodium（DVDMS）介导的光动力疗法（PDT）对比医生选择的治疗（TPC）用于晚期食管癌患者：一项 III 期、随机、开放标签、多中心试验会议类型：Rapid Oral Abstract Session摘要号：4016汇报者：周俊（北京大学肿瘤医院）05肝胆胰肿瘤Efficacy and safety of cafelkibart (LM-108), an anti-CCR8 monoclonal antibody, in combination with anti-PD-1 therapy in patients with pancreatic cancer: Results from phase 1/2 studies抗 CCR8 单克隆抗体 cafelkibart (LM-108) 联合抗 PD-1 疗法治疗胰腺癌患者的疗效和安全性：1/2 期研究结果会议类型：Clinical Science Symposium摘要号：4010汇报者：龚继芳（北京大学肿瘤医院）06泌尿男生殖肿瘤9MW2821, a novel Nectin-4 antibody-drug conjugate (ADC), combined with toripalimab in treatment-naïve patients with locally advanced or metastatic urothelial carcinoma (la/mUC): Results from a phase 1b/2 study一种新型Nectin-4抗体药物偶联物（ADC）9MW2821联合特瑞普利单抗治疗未经治疗的局部晚期或转移性尿路上皮癌（la/mUC）患者：一项1b/2期研究结果会议类型：Rapid Oral Abstract Session摘要号：4519汇报者：盛锡楠（北京大学肿瘤医院）07妇科肿瘤Sentinel lymph node biopsy versus pelvic lymphadenectomy in cervical cancer: The PHENIX trial宫颈癌前哨淋巴结活检 vs 盆腔淋巴结清扫术对比：PHENIX试验会议类型：Oral Abstract Session摘要号：LBA5501汇报者：刘继红（中山大学肿瘤防治中心）Benmelstobart plus carboplatin/paclitaxel with or without anlotinib, followed by maintenance benmelstobart with or without anlotinib, as first-line treatment for advanced or recurrent endometrial cancer: A randomized, open-label, phase II trial贝莫苏拜单抗联合卡铂/紫杉醇±安罗替尼，随后贝莫苏拜单抗±安罗替尼维持治疗用于晚期或复发性子宫内膜癌一线治疗：一项随机、开放标签、II期临床试验会议类型：Oral Abstract Session摘要号：5508汇报者：陈晓军（上海市第十人民医院）Cadonilimab plus platinum-based chemotherapy ± bevacizumab for persistent, recurrent, or metastatic cervical cancer: Subgroup analyses of COMPASSION-16卡度尼利单抗联合含铂化疗±贝伐单抗治疗持续性、复发性或转移性宫颈癌：COMPASSION-16 亚组分析会议类型：Rapid Oral Abstract Session摘要号：5509汇报者：吴小华（复旦大学肿瘤医院）Nimotuzumab combined with chemotherapy in the first-line treatment for patients with stage IVB, recurrent or persistent cervical squamous cell carcinoma: A multi-center, randomized, double-blind, and controlled study尼妥珠单抗联合化疗用于IVB期、复发性或持续性宫颈鳞癌一线治疗：一项多中心、随机、双盲、对照研究会议类型：Rapid Oral Abstract Session摘要号：5510汇报者：Zexuan Liu（中国医学科学院肿瘤医院）Safety and efficacy of BAT8006, a folate receptor α (FRα) antibody drug conjugate, in patients with platinum-resistant ovarian cancer: Update on the dose optimization/expansion cohort of BAT-8006-001-CR trial叶酸受体α（FRα）抗体药物偶联物BAT8006用于铂耐药卵巢癌患者的安全性和有效性：BAT-8006-001-CR试验剂量优化/扩展队列更新会议类型：Rapid Oral Abstract Session摘要号：5517汇报者：张松灵（吉林大学第一医院）08头颈鼻咽癌PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized controlled trial特瑞普利单抗联合诱导化疗和放疗±顺铂治疗局部晚期鼻咽癌的Ⅲ期非劣效性多中心随机对照试验（DIAMOND研究）会议类型：Oral Abstract Session摘要号：LBA6003汇报者：马骏（中山大学肿瘤防治中心）Becotatug vedotin vs. chemotherapy in pre-heavily treated advanced nasopharyngeal carcinoma: A randomized, controlled, multicenter, open-label studyBecotatug vedotin对比化疗治疗既往接受多线治疗的晚期鼻咽癌：一项多中心、随机、开放标签对照研究会议类型：Oral Abstract Session摘要号：LBA6005汇报者：韩非（中山大学肿瘤防治中心）Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study塔戈利单抗联合吉西他滨/顺铂治疗复发或转移性鼻咽癌的III期随机双盲研究会议类型：Oral Abstract Session摘要号：6004汇报者：石远凯（中国医学科学院肿瘤医院）SHR-A1811 in HER2-expressing salivary gland cancers: Preliminary efficacy and safety resultsSHR-A1811用于HER2表达型涎腺癌的初步疗效与安全性结果会议类型：Oral Abstract Session摘要号：6006汇报者：季冬梅（复旦大学附属肿瘤医院）Dynamic circulating tumor DNA-driven, risk-adapted systematic therapy in nasopharyngeal carcinoma: The EP-STAR trial基于动态循环肿瘤DNA的风险适应性全身治疗策略用于鼻咽癌：EP-STAR研究会议类型：Clinical Science Symposium摘要号：6010汇报者：孙颖（中山大学肿瘤防治中心）REMATCH2201: A phase II study on reducing surgical margins in HPV-negative advanced HNSCC with neoadjuvant PD-1 inhibitor and AP chemotherapyREMATCH2201研究：新辅助PD-1抑制剂联合AP方案化疗用于HPV阴性晚期头颈部鳞癌以缩小手术切缘的II期临床试验会议类型：Clinical Science Symposium摘要号：6011汇报者：杨坤禹（华中科技大学同济医学院附属协和医院）A randomized, open-label, multicenter, blank-controlled, phase IV clinical trial of Biyan Qingdu Granula in attenuating acute nose and oral damage in patients undergoing radiotherapy for nasopharyngeal carcinoma鼻咽清毒颗粒减轻鼻咽癌患者放疗相关急性鼻腔及口腔黏膜损伤的Ⅳ期、多中心、随机、空白对照、开放标签临床试验会议类型：Rapid Oral Abstract Session摘要号：6014汇报者：刘志刚（南方医科大学第十附属医院）Neoadjuvant PD-1 inhibitor combined with Nab-paclitaxel and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NCT05522985): A randomized, controlled, open label, phase II clinical trialPD-1抑制剂联合白蛋白紫杉醇和顺铂用于可切除局部晚期头颈部鳞癌的新辅助治疗：II期、随机、开放标签对照临床研究（NCT05522985）会议类型：Rapid Oral Abstract Session摘要号：6018汇报者：王红玲（天津医科大学肿瘤医院）09皮肤和黑色素瘤Efficacy and safety results of a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein IBI363 in patients (pts) with immunotherapy-treated, advanced acral and mucosal melanoma.首创新药 PD-1/IL-2α-bias双特异性抗体融合蛋白 IBI363 治疗经免疫治疗的晚期肢端和黏膜黑色素瘤患者的疗效和安全性结果会议类型：Oral Abstract Session摘要号：2502汇报者：郭军（北京大学肿瘤医院）Neoadjuvant camrelizumab plus apatinib and temozolomide for resectable stage II/III acral melanoma: The CAP 03-NEO trial新辅助卡瑞利珠单抗联合阿帕替尼和替莫唑胺治疗可切除的 II/III 期肢端黑色素瘤：CAP 03-NEO 试验会议类型：Rapid Oral Abstract Session摘要号：9512汇报者：毛丽丽（北京大学肿瘤医院）Rare Melanoma Subtypes: Where Do We Stand?罕见的黑色素瘤亚型：我们目前的认知程度如何？会议类型：Education Session演讲者：郭军（北京大学肿瘤医院）10骨和软组织肉瘤Pimicotinib in tenosynovial giant cell tumor (TGCT): Efficacy, safety and patient-reported outcomes of phase 3 MANEUVER study腱鞘巨细胞瘤 (TGCT) 中的匹米替尼：3 期 MANEUVER 研究的疗效、安全性和患者报告结果会议类型：Oral Abstract Session摘要号：11500汇报者：牛晓辉（北京积水潭医院）Anlotinib in combination with epirubicin followed by maintenance anlotinib versus placebo plus epirubicin as first-line treatment for advanced soft tissue sarcoma (STS): A randomized, double-blind, parallel-controlled, phase III study安罗替尼联合表柔比星治疗，随后进行安罗替尼维持治疗，与安慰剂加表柔比星治疗晚期软组织肉瘤 (STS) 的一线治疗相比：一项随机、双盲、平行对照的 III 期研究议类型：Oral Abstract Session摘要号：11501汇报者：周宇红（复旦大学附属中山医院）Eribulin plus anlotinib in advanced soft tissue sarcoma (ERAS): Updates on efficacy and biomarkers艾立布林联合安罗替尼治疗晚期软组织肉瘤（ERAS）：疗效和生物标志物的最新进展会议类型：Oral Abstract Session摘要号：11502汇报者：邓窈窕（四川大学华西医院）Camrelizumab plus apatinib in patients with advanced or refractory chordoma: A single-arm, open-label, phase 2 trial卡瑞利珠单抗联合阿帕替尼治疗晚期或难治性脊索瘤患者：一项单臂、开放标签、 2 期试验会议类型：Oral Abstract Session摘要号：11503汇报者：杨诚（海军军医大学附属长征医院）Evaluation of the safety and efficacy of ALMB-0168, a novel monoclonal antibody activating Cx43 hemichannel, for osteosarcoma after standard therapy failure: A multicenter, open-label, single agent, phase 1/2 study (ACE study)评估新型激活 Cx43 半通道单克隆抗体 ALMB-0168 在标准疗法失败后治疗骨肉瘤的安全性和有效性：一项多中心、开放标签、单药、1/2 期研究（ACE 研究）会议类型：Rapid Oral Abstract Session摘要号：11509汇报者：沈靖南（中山大学附属第一医院）Phase Ib trial of C019199, an oral TME modulator targeting CSF-1R/DDRs/VEGFR2, in relapsed or refractory osteosarcoma靶向CSF-1R/DDRs/VEGFR2的口服 TME 调节剂C019199治疗复发或难治性骨肉瘤的 Ib 期试验会议类型：Rapid Oral Abstract Session摘要号：11510汇报者：叶峰（厦门大学附属第一医院）11神经内分泌肿瘤Assessment of efficacy of LBL-024, a novel and uniquely designed bispecific antibody against PD-L1 and 4-1BB, combined with etoposide/platinum-based chemotherapy in treatment-naive advanced extrapulmonary neuroendocrine carcinoma (EP-NEC): A multicenter phase Ib/II trial评估LBL-024（一种针对PD-L1和4-1BB的新型双特异性抗体）联合依托泊苷/铂类化疗治疗未经治疗的晚期肺外神经内分泌癌（EP-NEC）的疗效：一项多中心Ib/II期试验会议类型：Oral Abstract Session摘要号：2500汇报者：张盼盼（北京大学肿瘤医院）12中枢神经系统肿瘤Efficacy and safety of STUPP regimen with or without anlotinib for newly diagnosed glioblastoma: Results of a multicenter, double-blind, randomized phase II trialSTUPP方案联合或不联合安罗替尼治疗新诊断胶质母细胞瘤的疗效和安全性：一项多中心、双盲、随机II期试验的结果会议类型：Oral Abstract Session摘要号：LBA2000汇报者：陈媛媛（中山大学肿瘤防治中心）13实体瘤新药Phase 1 trial of SHR-A2102, a nectin-4–directed antibody drug conjugate (ADC), in advanced solid tumors抗体药物偶联物（ADC）SHR-A2102 用于治疗晚期实体瘤的I期临床试验会议类型：Clinical Science Symposium摘要号：107汇报者：钟润波（上海市胸科医院）Effect of erythrocyte-antibody conjugates on cancers resistant to checkpoint blockade immunotherapy: A phase I trial红细胞抗体偶联物对检查点阻断免疫疗法耐药肿瘤的疗效：一项I期试验会议类型：Oral Abstract Session摘要号：2506汇报者：Xiaoqian Nie（西湖大学）Safety and efficacy of TQB2102, a novel bispecific anti-HER2 antibody–drug conjugate, in patients with advanced solid tumors: Preliminary data from the first-in-human phase 1 trial新型双特异性抗HER2抗体-药物偶联物TQB2102在晚期实体瘤患者中的安全性和有效性：首次人体1期试验的初步数据会议类型：Oral Abstract Session摘要号：3003汇报者：徐瑞华（中山大学肿瘤防治中心）A first-in-human phase I/II study of GFH375, a highly selective and potent oral KRAS G12D inhibitor in patients with KRAS G12D mutant advanced solid tumors一种高选择性、强效口服 KRAS G12D 抑制剂GFH375治疗 KRAS G12D 突变晚期实体瘤患者的首次人体I/II期研究会议类型：Rapid Oral Abstract Session摘要号：3013汇报者：艾星浩（上海市胸科医院）14血液系统恶性肿瘤Revision of staging system for natural killer T-cell lymphoma: A multicenter study from the Chinese Southwest Oncology Group and Asia Lymphoma Study Group自然杀伤性 T 细胞淋巴瘤分期系统修订：中国西南肿瘤学组及亚洲淋巴瘤研究组多中心研究会议类型：Oral Abstract Session摘要号：7001汇报者：林桐榆（四川省肿瘤医院）Molecular landscape of distinct follicular lymphoma histologic grades: Insights from genomic and transcriptome analyses不同组织学分级滤泡性淋巴瘤的分子图谱：来自基因组和转录组分析的见解会议类型：Oral Abstract Session摘要号：7002汇报者：孙聪（天津医科大学肿瘤医院）Sintilimab (anti-PD-1 antibody) combined with chidamide (an oral subtype-selective HDACi) followed by P-GemOx regimen in patients with treatment-naïve extranodal natural killer/T cell lymphoma (TN-ENKTL): A multicenter, open-label, single-arm, phase II study (SCENT-2 trial)信迪利单抗（抗PD-1抗体）联合西达本胺（一种口服HDACi）继以 P-GemOx 方案治疗初治结外自然杀伤性 /T 细胞淋巴瘤（TN-ENKTL）患者的多中心、开放标签、单臂、II 期研究（SCENT-2 试验）会议类型：Oral Abstract Session摘要号：7006汇报者：黄慧强（中山大学肿瘤防治中心）Sintilimab (anti-PD-1) plus ifosfamide, carboplatin, and etoposide (ICE) in second-line classical Hodgkin lymphoma (cHL): Results of a multicenter, randomized, controlled, double-blind phase 3 study (ORIENT-21)信迪利单抗（抗PD-1）联合依托泊苷（ICE）方案用于二线治疗经典霍奇金淋巴瘤（cHL）：一项多中心、随机、对照、双盲 III 期研究（ORIENT-21）的结果会议类型：Oral Abstract Session摘要号：7007汇报者：刘鹏（中国医学科学院肿瘤医院）Phase 1/2 studies of DZD8586 in CLL/SLL patients after covalent or non-covalent BTK inhibitors and BTK degradersDZD8586 在经共价或非共价 BTK 抑制剂及 BTK 降解剂治疗后的 CLL/SLL 患者中的I/II期研究会议类型：Rapid Oral Abstract Session摘要号：7010汇报者：李建勇（江苏省人民医院）A phase 1/2 study to evaluate the safety and efficacy of XNW5004, a selective EZH2 inhibitor, in subjects with relapsed/refractory non-Hodgkin lymphoma一项1/2期研究：评估选择性 EZH2 抑制剂 XNW5004 在复发 / 难治性非霍奇金淋巴瘤患者中的安全性与有效性会议类型：Rapid Oral Abstract Session摘要号：7012汇报者：邱录贵 [中国医学科学院血液病医院（中国医学科学院血液学研究所）]CD79b-targeted antibody-drug conjugate (ADC) SHR-A1912 in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx) in relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL): Data from a phase 1b/2 study以 CD79b 为靶点的抗体偶联药物（ADC）SHR - A1912 联合R - GemOx方案用于复发 / 难治性（R/R）弥漫性大 B 细胞淋巴瘤（DLBCL）患者的1b/2期研究数据会议类型：Rapid Oral Abstract Session摘要号：7013汇报者：李亚军（湖南省肿瘤医院）Worldwide experience of chronic active EBV infection: Retrospective cohort study全球慢性活动性EBV感染经验：回顾性队列研究会议类型：Rapid Oral Abstract Session摘要号：7016汇报者：王欣然（华中科技大学同济医学院附属同济医院）Preliminary results from the dose-escalation stage of a phase I trial of an anti-CCR8 antibody in patients with relapsed/refractory cutaneous T-cell lymphoma (R/R CTCL)靶向CCR8抗体治疗复发/难治性皮肤T细胞淋巴瘤（R/R CTCL）的Ⅰ期临床试验剂量递增阶段初步结果会议类型：Rapid Oral Abstract Session摘要号：2514汇报者：李志铭（中山大学肿瘤防治中心）15症状科学和姑息治疗Efficacy of treatment with traditional Chinese medicine (Renshen Yangrong Tang granules) for cancer-related fatigue in patients with platinum-based chemotherapy: A randomized, double- blinded, placebo-controlled, multicenter tria中药（人参养荣汤颗粒）治疗接受铂类化疗患者癌因性疲乏的疗效：一项随机、双盲、安慰剂对照、多中心试验会议类型：Rapid Oral Abstract Session摘要号：12012汇报者：Yichen Xu（北京大学肿瘤医院）16癌症护理Electronic patient-reported outcome-based weight management versus usual care during induction chemotherapy followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma: A phase II randomized controlled trial基于电子化的患者体重管理与常规护理在鼻咽癌患者诱导化疗后同步放化疗期间的比较：一项 Ⅱ 期随机对照试验会议类型：Oral Abstract Session摘要号：1503汇报者：陈秋燕（中山大学肿瘤防治中心）（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

ASCO会议临床3期临床2期临床结果

2025-03-31

·医学新视点

预测总生存期延长超过一年，组合疗法有望为肺癌患者带来新选择

▎药明康德内容团队编辑强生公司（Johnson & Johnson）近日公布了3期临床试验MARIPOSA的总生存期（OS）结果。试验结果显示，其双特异性抗体疗法Rybrevant（amivantamab）与Lazcluze（lazertinib）联用，一线治疗具有表皮生长因子受体（EGFR）19号外显子缺失（ex19del）或L858R替代突变的局部晚期或转移性非小细胞肺癌（NSCLC）患者时，显著延长了患者的总生存期。MARIPOSA是一项评估Rybrevant/Lazcluze组合一线治疗携带特定EGFR变异的NSCLC患者的3期临床试验。数据显示，在中位随访时间为37.8个月时，与活性对照组相比，Rybrevant/Lazcluze组合将患者死亡风险降低25%（HR=0.75；95% CI：0.61–0.92）。Rybrevant/Lazcluze组的中位OS尚未达到，而活性对照组中位OS为36.7个月。接受Rybrevant/Lazcluze组合治疗的患者中，有56%在3.5年时仍然存活，而活性对照组为44%。基于生存数据的预测显示，与活性对照相比，Rybrevant/Lazcluze可将中位OS至少延长12个月。Rybrevant是一款人源化EGFR/MET靶向双特异性抗体。它具有多重抗癌的作用机制，不但能够阻断EGFR和MET介导的信号传导，还可以引导免疫细胞靶向携带激活性和耐药性EGFR/MET突变和扩增的肿瘤。Lazcluze是一种具高选择性、可穿越血脑屏障的第三代口服EGFR酪氨酸激酶抑制剂。推荐阅读超1/4患者生存突破5年，5年病情无进展患者比例翻6倍之多！周彩存教授：卡瑞利珠单抗联合化疗或重塑肺癌患者治疗选择上海市东方医院/上海市肺科医院周彩存领衔研究登《柳叶刀》：新药使肺癌患者疾病进展或死亡风险降低49%！《自然-医学》：检出率高达84.8%！吴一龙团队研究：预测肺癌脑转移患者生存期，有望指导临床治疗选择97%患者肿瘤缩小，疾病控制率达99%！上海市胸科医院陆舜团队领衔：ADC为肺癌患者带来新选择参考资料：[1] 1O - Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD. Retrieved March 20, 2025, from https://cslide.ctimeetingtech.com/coasis_21204/attendee/confcal/show/session/11免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，传递医学新知

临床3期临床结果抗体药物偶联物

2025-03-30

·医学新视点

64%获得缓解患者9个月时维持疗效！新药有望为肺癌患者添新选择

▎药明康德内容团队编辑近期，阿斯利康（AstraZeneca）公司在2025年欧洲肺癌大会（ELCC）的摘要中公布了该公司与第一三共（Daiichi Sankyo）联合开发的抗体偶联药物datopotamab deruxtecan（Dato-DXd），与EGFR抑制剂奥希替尼联用，2线治疗EGFR突变非小细胞肺癌患者的2期临床试验结果。这些患者在接受一线奥希替尼治疗后疾病进展。数据显示，在接受奥希替尼加剂量为4 mg/kg的Dato-DXd治疗的35名患者中，客观缓解率（ORR）为43%；在接受奥希替尼加剂量为6 mg/kg的Dato-DXd治疗的34名患者中，ORR为36%。在6 mg/kg剂量组，中位无进展生存期（PFS）为11.7个月，64%获得缓解的患者在9个月时维持缓解。4 mg/kg剂量组的中位PFS为9.5个月，15%获得缓解的患者在9个月时维持缓解。研究人员在摘要中表示，基于整体获益/风险比，推荐使用6 mg/kg剂量用于后续研究。Dato-DXd是一款靶向Trop2的抗体偶联药物，已经获得美国FDA的批准用于治疗HR阳性、HER2阴性的经治成年乳腺癌患者。推荐阅读上海市东方医院/上海市肺科医院周彩存领衔研究登《柳叶刀》：新药使肺癌患者疾病进展或死亡风险降低49%！《自然-医学》：检出率高达84.8%！吴一龙团队研究：预测肺癌脑转移患者生存期，有望指导临床治疗选择JCO：新药对肺癌、乳腺癌等多种实体瘤均有效！30%患者肿瘤部分消失，效果维持近13个月97%患者肿瘤缩小，疾病控制率达99%！上海市胸科医院陆舜团队领衔：ADC为肺癌患者带来新选择参考资料：[1] 1O - Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD. Retrieved March 20, 2025, from https://cslide.ctimeetingtech.com/coasis_21204/attendee/confcal/show/session/11免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，传递医学新知

抗体药物偶联物临床2期

100 项与上海市肺科医院相关的药物交易

登录后查看更多信息

100 项与上海市肺科医院相关的转化医学

登录后查看更多信息